Has Hector Miranda Delgado, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,834 in general payments to Hector Miranda Delgado, MD across 43 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Hector Miranda Delgado, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Hector Miranda Delgado, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Hector Miranda Delgado, MD

Neurology · San Juan, PRNPI 1609847763

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Novartis at 59.6% of the total. Reporting peaked in 2019 at $4,104 and has fallen 95.5% since, to $184 in 2025.

$5,834in general payments, 2019–2025

Across 43 payments — averaging $135.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$3K
EMD Serono, Inc.$1K
Amgen$416
Biogen$290
Johnson & Johnson$200
E.r. Squibb & Sons, L.L.C.$81
plus $137 from 4 others

$1,500in research payments, 2019–2025

Across 1 payment — averaging $1500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$2K

What the payments were for

Speaking & faculty fees$3,37558%
Travel & lodging$2665%
Food & beverage$2,19338%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	2	$3,475
EMD Serono, Inc.	18	$1,235
Amgen	3	$416
Biogen	7	$290
Johnson & Johnson	2	$200
E.r. Squibb & Sons, L.L.C.	4	$81
PBG Puerto Rico LLC	3	$59
AbbVie	2	$44
Genentech USA, Inc.	1	$20
Pfizer Pharmaceuticals LLC	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AIMOVIG$3,891
Mavenclad$609
XARELTO$200

How this compares

$5,834 in reported general payments places this provider in the 80th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$95,438

Medicare patients

Services billed

2,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Memantine Hcl ErMemantine Hcl	673	$51,399
Etodolac ErEtodolac	343	$38,688
LamictalLamotrigine	22	$28,860
Duloxetine Hcl	1,037	$18,337
Pregabalin	582	$16,362
Carbidopa-Levodopa ErCarbidopa/Levodopa	288	$16,141
Nabumetone	615	$14,642
Donepezil Hcl	1,414	$10,898
Rivastigmine	92	$10,872
ClopidogrelClopidogrel Bisulfate	989	$7,832
Memantine Hcl	388	$5,943
Clorazepate Dipotassium	36	$5,924
Pregabalin ErPregabalin	25	$5,594
Diclofenac Potassium	61	$5,376
Galantamine ErGalantamine Hbr	95	$5,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieSynthroid	$44	$1,56532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 129 neurology providers in Puerto Rico.

Other neurology in San Juan

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →